Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

431
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
431
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

479
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
479
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

600
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
600
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Antiplatelet Therapy: The Promise and Complexity of Pharmacogenomic Antiplatelet Therapy.

Circulation. Cardiovascular interventions·2026
Same author

Diabetes and cancer: therapeutic implications.

Cardio-oncology (London, England)·2026
Same author

Measuring Adherence to Multiple Medications Using Guideline-Directed Medical Therapy as a Model.

medRxiv : the preprint server for health sciences·2025
Same author

Assessing Medical Therapy Optimization in Cardiovascular-Kidney-Metabolic Clinical Trials: An Initiative From the Heart Failure Collaboratory.

JACC. Heart failure·2025
Same author

Platelet reactivity expression score in diabetes mellitus.

Blood vessels, thrombosis & hemostasis·2025
Same author

Accuracy of Electronic Health Record-Based Definitions for Patients with Heart Failure.

The American journal of medicine·2025

Related Experiment Video

Updated: Mar 3, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Heart Failure Guidelines on Pharmacotherapy.

Lampros Papadimitriou1, Carine E Hamo2, Javed Butler2

  • 1Division of Cardiology, Stony Brook Medicine, Health Sciences Center T-16, Room 080, Stony Brook, NY, 11794, USA. lampros.papadimitriou@stonybrookmedicine.edu.

Handbook of Experimental Pharmacology
|April 29, 2017
PubMed
Summary
This summary is machine-generated.

Heart Failure (HF) significantly impacts public health, affecting millions and incurring substantial costs. This review details medications proven to reduce mortality and morbidity in HF patients, referencing North American guidelines.

Keywords:
GuidelinesHFrEFHeart failureStage C

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Related Experiment Videos

Last Updated: Mar 3, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.1K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacology

Background:

  • Heart Failure (HF) presents a significant public health challenge, particularly in high-income nations.
  • Over 6 million adults in the USA are affected by HF, incurring substantial healthcare costs and high mortality rates.
  • Despite therapeutic advancements, HF remains a major burden on healthcare systems.

Purpose of the Study:

  • To review medications proven to reduce mortality and morbidity in Heart Failure patients.
  • To align with the latest North American Heart Failure guidelines.
  • To compare current recommendations with the 2016 European Society of Cardiology guidelines.

Main Methods:

  • Literature review of medications for Heart Failure.
  • Analysis based on North American Heart Failure guidelines.
  • Comparative analysis of North American and European Society of Cardiology guidelines.

Main Results:

  • Identified key medications significantly reducing mortality and morbidity in HF patients.
  • Highlighted adherence to North American Heart Failure guidelines.
  • Provided a comparative overview of guideline recommendations.

Conclusions:

  • Specific medications are crucial for managing Heart Failure and improving patient outcomes.
  • Guidelines from North America and Europe offer valuable, comparable strategies for HF management.
  • Continued adherence to evidence-based guidelines is essential for mitigating the impact of Heart Failure.